Drug · DIN 02381702
ACT RIZATRIPTAN
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since May 6, 2020; first marketed June 14, 2012.
- Drug Identification Number (DIN)
- 02381702
- Company (DIN owner)
- Teva Canada LimitedToronto, Ontario, Canada
- Schedule
- Prescription
- Dosage form
- Tablet
- Route
- Oral
- Therapeutic class (ATC)
- Rizatriptan N02CC04
- Class
- Human
- Record last updated
- March 22, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| RIZATRIPTAN (RIZATRIPTAN BENZOATE) | 10 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- May 6, 2020: NOC 23574Abbreviated New Drug Submission (ANDS) · Merger- buyout. licensing agreement betwee two companies
- October 30, 2014: NOC 16241Abbreviated New Drug Submission (ANDS) · Manufacturer and product name change
- March 30, 2012: NOC 13167Abbreviated New Drug Submission (ANDS) · New manufacturer and product name
Other DINs named ACT RIZATRIPTAN
- DIN 02381699 · Approved